We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed at $51.96 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily loss of 0.21%. Elsewhere, the Dow lost 0.16%, while the tech-heavy Nasdaq lost 0.89%.
Shares of the drugstore chain and pharmacy benefits manager have appreciated by 15.15% over the course of the past month, outperforming the Retail-Wholesale sector's loss of 2.84% and the S&P 500's loss of 1.56%.
Market participants will be closely following the financial results of CVS Health in its upcoming release. The company plans to announce its earnings on February 12, 2025. It is anticipated that the company will report an EPS of $0.94, marking a 55.66% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $97.27 billion, indicating a 3.69% growth compared to the corresponding quarter of the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CVS Health. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.08% lower within the past month. CVS Health is currently a Zacks Rank #5 (Strong Sell).
From a valuation perspective, CVS Health is currently exchanging hands at a Forward P/E ratio of 8.56. This indicates a premium in contrast to its industry's Forward P/E of 7.89.
It's also important to note that CVS currently trades at a PEG ratio of 0.78. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Retail - Pharmacies and Drug Stores industry had an average PEG ratio of 0.78.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 235, putting it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Suffers a Larger Drop Than the General Market: Key Insights
CVS Health (CVS - Free Report) closed at $51.96 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily loss of 0.21%. Elsewhere, the Dow lost 0.16%, while the tech-heavy Nasdaq lost 0.89%.
Shares of the drugstore chain and pharmacy benefits manager have appreciated by 15.15% over the course of the past month, outperforming the Retail-Wholesale sector's loss of 2.84% and the S&P 500's loss of 1.56%.
Market participants will be closely following the financial results of CVS Health in its upcoming release. The company plans to announce its earnings on February 12, 2025. It is anticipated that the company will report an EPS of $0.94, marking a 55.66% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $97.27 billion, indicating a 3.69% growth compared to the corresponding quarter of the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CVS Health. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.08% lower within the past month. CVS Health is currently a Zacks Rank #5 (Strong Sell).
From a valuation perspective, CVS Health is currently exchanging hands at a Forward P/E ratio of 8.56. This indicates a premium in contrast to its industry's Forward P/E of 7.89.
It's also important to note that CVS currently trades at a PEG ratio of 0.78. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Retail - Pharmacies and Drug Stores industry had an average PEG ratio of 0.78.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 235, putting it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.